Abbott Laboratories may see boost from St. Jude's acquisition: Barron's

Abbott Laboratories is likely to see its shares rise again after trading range-bound for nearly a year on the back of its $25 billion acquisition of medical device-maker St. Jude Medical, Barron's said on Sunday. The global healthcare company, based in Abbott Park, Illinois, has seen its stock trade between $37 and $45 for a year, as investors remain concerned over currency headwinds given the company's global business and its St. Jude acquisition. The St. Jude deal, which closed last month, has